Regeneron bets added cholesterol benefit will help its obesity drug stand out

By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' executives voiced confidence in its ...
Seeking Alpha

Sanofi reportedly halts sales of cholesterol drug Praluent in China amid limited availability

Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as surging demand has caused availability issues, Reuters reported on Tuesday, ...
Becker's Hospital Review

Judge orders Sanofi, Regeneron’s cholesterol drug off the market following patent dispute

U.S. District Judge Sue Robinson of Delaware on Jan. 5 granted Amgen’s request for a permanent injunction to block Sanofi and Regeneron Pharmaceuticals from marketing its cholesterol drug Praluent, ...
Becker's Hospital Review

FDA OKs monthly dosing option for Praluent

The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent. The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA ...
AOL

Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...
Nasdaq

Regeneron Pharmaceuticals Celebrates Jury Verdict Against Amgen for Antitrust Violations, Awarding $406.8 Million in Damages

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc. violated ...